Highlights in the Quarter include:
1. Future growth of HCV remains a worry point for some analysts, particularly in
Europe where there was a decline. Some of the EU decline may be an artifact of the
summer holiday. We see tremendous potential now in Japan to be a growth focus
area. Express Scripps (ESRX $84.05-Buy rated) was mentioned but we don't see
any changes in 2016 as likely for preferential treatment given to AbbVie (ABBV -
$52.58 - NR) Viekira Pak which hit some selected toxicity issues that will impact its
label, however doctors tell us they see Harvoni as the HCV regimen of choice.
Gilead delivered a very strong quarter well ahead of street estimates and our own numbers with Product sales of $8.2 billion versus our estimates of $7.8B. Just about every product area was ahead of our estimates and Solvadi / Harvoni at $4.8B versus consensus at $4.5B (although we are hearing some analysts talking about slowing sequential growth). Gilead raised guidance for full year revenues in a new range $30-$31B ( from $29-$30B). All other guidance remained unchanged from 2QTR.
Conclusion: Gilead continues to be the leader in our Biotechnology universe. A consistent base (HIV) with HCV driving growth. The company continues to develop its "other" franchises as HCV outshines. We see upside as Japan starts to build. We are rolling our model forward to 2016 which pushes our price target from $129 to $137 per share.
Mac has been right since last September. Something you and everyone here cannot Refute!. Deal with it.
My 2 shorts gonna work out No later than Friday this week!
That's why the Deal would take until Q2 of 2016 to close. Sneaky Goldman Sachs removed SNDK from its Conviction Buy list a couple weeks ago while loading up on the cheap. Now they act as Financial Adviser!LOL. I won't sell my remaining shares until I see fair value of this stock which should be around the high 90s.
SNCK I remember you perfectly. How are things in Arizona?. 10 years ago is a long time. The old timers who bought SNDK in the single digit and the low teens were mostly gone. Good to hear from you again!
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1.
Estimated Enrollment: 70
Study Start Date: December 2014
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Primary Outcome Measures:
Safety Data: Number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results [ Time Frame: From screening to Day 8 (SAD/FE) and Day 21 (MAD) ] [ Designated as safety issue: Yes ]
Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results (including chemistry, hematology, and urine).
Secondary Outcome Measures:
Single Dose PK: Cmax, tmax, t1/2, CL/F and Vz/F (for AL-335 only), AUC0-inf or AUClast [ Time Frame: From dosing to Day 8 visit for each SAD/FE cohort ] [ Designated as safety issue: No ]
PK parameters of AL-335, and metabolites following single dose administration: Cmax, tmax, t1/2, CL/F and Vz/F (for AL-335 only), AUC0-inf or AUClast
Multiple Dose PK: Cmax, tmax, t1/2, AUClast and AUC0 tau [ Time Frame: From dosing to final study visit (21 days) for each cohort ] [ Designated as safety issue: No ]
• PK parameters of AL-335, ALS-022399, ALS-022227 (and other metabolites if applicable) following repeat dose administration: Cmax, tmax, t1/2, AUClast and AUC0 tau
Hepatitis C viral levels [ Time Frame: From screening to final study visit (21 days) for each cohort ] [ Designated as safety issue: No ]
HCV ribonucleic acid (RNA) viral load change from baseline to final study visit in subjects with CHC infection
Toshiba would not let their long standing partner SanDisk goes so easily. Your original nick as I remember is joe52us. We were in this stock through Thick and Thin for a good 10 years. Do you remember it was Toshiba who practically gave SNDK back the 1.2 billion Fab4 investment when they had 2 consecutive losses back in 2004. Then Samsung made a bit for 25 bucks when SNDK traded in the low 10s.
Watch Toshiba makes a counter offer if there is talk between SanDisk and WDC.
Who to believe anymore?LOL. During last presentation Desh stated DDI studies with AL-335 and 3102+/- Simeprevir would take until the end of 2016 to complete. Now Alios would forge ahead with Phase 2a without releasing POC Data of AL-335. Total disarray. It's like Desh was talking about Horses' Butt and the CEO of Alios responded with Cow Dung to Desh!LMAO.
Where is that Flapping Lurker Boy hidding?...Behind Oleo Milfie Igobonker's skirt???
Yup when JNJ finally has a viable regimen to sell; a full course of HepC treatment will cost around 20k not counting Indian Generic makers would flood the world Market with an Effective Bio similar. Ask yourself what Royalties Achillion is expecting from the Sale. Desh, your CEO knew that so money in the bank first would secure his Royal Pay for years to come. You guys are getting the short end of the Stick and you don't even know it!LOL.
the HepC Field. Others are late to the party
' We find the 89% SVR4 encouraging in treatment-naïve cirrhotic GT3 patients from a 6-week treatment duration with Gilead’s’s triple combo (Sofosbuvir + GS-5816 + GS-9857). This is a high-end SVR relative to the historical rates in a very difficult patient population. Although the data are based off relatively small numbers of patients, the fact that the combo printed 100% SVR4 in GT3 treatment-experienced cirrhotics (even harder to treat) with 8 weeks’ duration suggests this combo is going to do very well in ph3 registrational studies in all GT’s, with short duration. In our view, this initial data suggests that Wave-4 works, and we continue to think it could hit the market by 2017 and support Gilead’s continued dominance in HCV (though we model lots of competition). At the conference, we look to the full SVR12 data for all groups, as well as data from Merck’s (MRK) triple (which appears to be a late-breaker).'
There is No News nor any catalyst in any foreseen Future. This Shameless Pumper is now the spoke person for Old Hag Magpie aka magnam_pi who have been misleading this board since last September.
these dudes and dudettes have No Integrity what so ever.
You Shameless Pumper.What Plethora of News?. Name one. You buy it's your money but DO NOT mislead others like Old Hag Magpie. Have you No Shame Wanton Cart Pusher!LMAO.
This stock shouldn't be trading at this level considering the outstanding number of shares divided by cash on hand. Any Milestones stone payment would not come until the year 2020 to 2022 if all Trials by Janssen gone well. The stock should be traded at cash value at best.
Time will tell if I am right on this projection.
They won't need another Dilution for any foreseen Future as the Money from JNJ will heir guaranteed their lavish Lifestyle for years to come. The Extra 8000 square feet of so called office Space!!! Why??. More perks for Achillion LaLa Land where a Heated Pool festonned with Gazebos and Fake Palm Trees are the ticket for Employees' Morale. Hey after a long day at work (what Work???); Desh needs to relax. A 1985 Dom Perignon, well iced a routine afternoon Drink. Maybe a few more Dolls for Desh;s Aerobics Lap dance to round out his hard day at his Opulent Office!....A Job well Done as usual!LMFAO.
Say it again mr.KnowNothing. Which Phase 1 (In Human) is completed. Where is the Data for such Phase1 Football head??. At last November 2014 AASLD presentation, Alios only gave out Cell based Replicon Assay. In other word, an In Vitro testing you Fool.!LMFAO.